Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Metabolomics in cancer research and emerging applications in clinical oncology
Cancer has myriad effects on metabolism that include both rewiring of intracellular
metabolism to enable cancer cells to proliferate inappropriately and adapt to the tumor …
metabolism to enable cancer cells to proliferate inappropriately and adapt to the tumor …
Tumour fatty acid metabolism in the context of therapy resistance and obesity
Fatty acid metabolism is known to support tumorigenesis and disease progression as well
as treatment resistance through enhanced lipid synthesis, storage and catabolism. More …
as treatment resistance through enhanced lipid synthesis, storage and catabolism. More …
Metabolic codependencies in the tumor microenvironment
P Dey, AC Kimmelman, RA DePinho - Cancer Discovery, 2021 - AACR
Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This
reprogramming is driven by the combined actions of oncogenic alterations in cancer cells …
reprogramming is driven by the combined actions of oncogenic alterations in cancer cells …
[HTML][HTML] Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
With the advent of effective tools to study lipids, including mass spectrometry-based
lipidomics, lipids are emerging as central players in cancer biology. Lipids function as …
lipidomics, lipids are emerging as central players in cancer biology. Lipids function as …
Genetics and biology of prostate cancer
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
Genomic hallmarks of localized, non-indolent prostate cancer
Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …
[HTML][HTML] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
T Chandrasekar, JC Yang, AC Gao… - … andrology and urology, 2015 - ncbi.nlm.nih.gov
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
The recent outbreak of infections and the pandemic caused by SARS-CoV-2 represent one
of the most severe threats to human health in more than a century. Emerging data from the …
of the most severe threats to human health in more than a century. Emerging data from the …
Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories
Identifying the earliest somatic changes in prostate cancer can give important insights into
tumor evolution and aids in stratifying high-from low-risk disease. We integrated whole …
tumor evolution and aids in stratifying high-from low-risk disease. We integrated whole …